Abstract
Transarterial microembolization (TAME) has gained recognition as a minimally invasive treatment for chronic musculoskeletal pain, demonstrating significant efficacy with a favorable safety profile ( 1, 2). However, complications remain underreported. This case report describes the first documented severe adverse event in a patient with a chronic venous ulcer undergoing TAME for a micro arteriovenous fistula (AVF). The patient developed significant complications, including extensive leg swelling, skin changes, and cellulitis requiring prolonged inpatient care. These findings highlight the importance of patient selection and embolic agent considerations to mitigate potential risks associated with TAME.